Starossom et al. also showed that exogenous Gal-1 significantly reduced EAE disease severity and microglia activation in the spinal cord in vivo, indicating that targeting the Gal-1-glycan axis may be a new therapeutic strategy for diseases involving oxidative stress neurodegeneration, such as MS. The gene discussed is GAL; the disease is myeloid sarcoma.